Clinical Trial Search

Primary: Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST) — 27; 24; 22; 22 Participants — p== 0.8439

Primary: Mortality — 17; 7 Participants

Primary: Part 1: Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) for PvP001 and PvP002 — 0; 0; 0; 0 Participants

Primary: (-/+)-M1, AUC(0-32) and AUC(Inf) — 136.0; 274.9; 408.8; 450.7 ng*hr/mL

Primary: Subjective Ratings on Lens Handling on Removal — 8.6; 8.5 units on a scale

Primary: Change in Moderate-to-Vigorous Minutes of Physical Activity Per Week — 27.4; 83.0; 88.4; 54.5 Minutes of physical activity

Primary: Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6 — 3.16; -21.08 Percent Change — p=<0.0001

Primary: Pain-related Fear and Avoidance — 32.36; 30.03; 25.15; 25.64 score on a scale — p=<0.05

Primary: Actigraphy (Total Sleep Time) — 7.08; 7.03; 7.16; 7.01 Time (hours.minutes of nightly sleep)

Primary: Vertiflex® Patient Satisfaction Survey — 1147 Participants

Primary: Bleeding — 14; 15; 15 Participants

Primary: Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period — -16.61 Percent change

Primary: Change in International Index of Erectile Function (IIEF) Scores — 0; 0; 0 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 6; 6; 6 Participants

Primary: Number of Participants Not Infected by COVID-19 — 100; 100 Participants — p=<0.01